Back to School: How biopharma can reboot drug development. Access exclusive analysis here

MTC-DOX: Phase I/II

Data from 16 patients in FeRx's U.S. Phase

Read the full 89 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE